Table 1 Demographic and characteristics of the study subjects.
Variables | Discovery set (N = 4210) | Statistics | P-value | Validation set (N = 2237) | Statistics | P-value | ||
|---|---|---|---|---|---|---|---|---|
Patients (N = 1668) | Controls (N = 2542) | Patients (N = 745) | Controls (N = 1492) | |||||
Age, years | 32.6 ± 11.5 | 32.5 ± 11.8 | t = 0.12 | 0.91 | 35.7 ± 13.0 | 35.7 ± 13.7 | t = − 0.03 | 0.98 |
Sex (%) | ||||||||
Male | 981 (59) | 1494 (59) | 466 (63) | 933 (63) | ||||
Female | 687 (41) | 1048 (41) | χ2 = 0.00 | 1.00 | 279 (37) | 559 (37) | χ2 = 0 | 1.00 |
Family history (%) | ||||||||
Yes | 220 (13) | 331 (13) | 80 (11) | 162 (11) | ||||
No | 1448 (87) | 2211 (87) | χ2 = 0.01 | 0.91 | 665 (89) | 1330 (89) | χ2 = 0.0002 | 0.99 |
Leukotrichia (%) | ||||||||
Yes | 262 (16) | 281(11) | 228 (31) | 81 (5) | ||||
No | 1282 (84) | 2385(89) | χ2 = 35.4 | < 0.01 | 517 (69) | 1411(95) | χ2 = 262.41 | < 0.01 |
Residence (%) | ||||||||
Rural | 445 (27) | 680 (27) | 255 (34) | 512 (34) | ||||
Urban | 1223 (73) | 1862 (73) | χ2 = 0.0003 | 0.99 | 490 (66) | 980 (66) | χ2 = 0.00 | 1.00 |
Onset (%) | ||||||||
Sudden | 382 (23) | – | – | – | 221 (30) | – | – | – |
Gradual | 1286 (77) | – | – | – | 524 (70) | – | – | – |
Disease type (%) | ||||||||
Generalized | 643 (39) | – | – | – | 252 (34) | – | – | – |
Acrofacial | 574 (34) | – | – | – | 288 (39) | – | – | – |
Mucosal | 262 (16) | – | – | – | 126 (17) | – | – | – |
Universal | 189 (11) | – | – | – | 79 (10) | – | – | – |
NSV disease activity (%) | ||||||||
0 | 396 (24) | – | – | – | – | – | – | – |
1 | 393 (24) | – | – | – | 237 (32) | – | – | – |
2 | 318 (19) | – | – | – | 184 (25) | – | – | – |
3 | 306 (18) | – | – | – | 144 (19) | – | – | – |
4 | 255 (15) | – | – | – | 180 (24) | – | – | – |
NSV Area Severity Index | ||||||||
Pre-treatment | 3.76 ± 1.85 | – | – | – | 4.53 ± 1.85 | – | – | – |
Post-treatment | – | – | – | 3.30 ± 1.73 | – | – | – | |
Serum level of NRIH3, μg/ml | – | – | – | 5.18 ± 1.12 | 2.73 ± 0.51 | – | – | |
